[Prevalence of Clostridium difficile and toxin A in feces of HIV infected patients].
Patients with AIDS are immunodeficient, receive multiple antibiotic treatments, occasionally anti-cancer chemotherapy and are often hospitalised; thus they are susceptible to develop a Clostridium difficile infection. The aim of this study was to evaluate the role of C. difficile in diarrhoea in this patient population. Therefore, C. difficile and toxin A which plays a major role in pathogenicity were examined in faecal samples of HIV infected patients. Between January 1991 and June 1992, 102 stool samples from 67 patients were studied. Ninety p. cent of these patients were hospitalised (length > 3 days), 80% had a diagnosis of AIDS stage IV, and 66% had diarrhoea. Nineteen point four p. cent of the patients were carriers of C. difficile. Different associations were found: 1) presence of non toxigenic strains and absence of toxin A in stool samples (6 patients), 2) presence of toxigenic strains and absence of toxin A in stool samples (6 patients), 3) presence of toxigenic strains and toxin A in stool samples (2 patients). None of the patients developed a colitis or pseudomembranous colitis. The carrier rate was identical to those found in other hospitalised populations without AIDS. The prevalence of C. difficile diarrhoea or colitis is low. In this study, AIDS patients do not seem to constitute a risk group for C. difficile intestinal pathology. However, carriers of C. difficile were subjected to strict hygiene rules to prevent nosocomial spread.
Collignon
A
A
Service de Bactériologie, Hôpital Jean Verdier, Bondy, France.
Jeantils
V
V
Cruaud
P
P
Javoy
F
F
Thomas
M
M
Torlotin
J C
JC
D017088:AIDS-Related Opportunistic Infections / Q000150:complications / Q000453:epidemiology / Q000382:microbiology; D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D001427:Bacterial Toxins / Q000302:isolation & purification*; D016360:Clostridioides difficile / Q000302:isolation & purification*; D004761:Enterocolitis, Pseudomembranous / Q000150:complications / Q000453:epidemiology* / Q000382:microbiology; D005243:Feces / Q000737:chemistry / Q000382:microbiology*; D015658:HIV Infections / Q000150:complications; D006801:Humans; D015995:Prevalence
D001427:Bacterial Toxins
Prévalence de Clostridium difficile et de la toxine A dans les selles de patients VIH positifs.